证券代码：601607 证券简称：上海医药 编号：临2025-077 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药第一生化药业有限公司（以下简称"上药第一生化"）生产的缩宫素 注射液及醋酸奥曲肽注射液收到菲律宾食品药品监督管理局颁发的药品注册证 书，前述药品获得批准上市。 上海医药集团股份有限公司 关于缩宫素注射液及醋酸奥曲肽注射液 获得菲律宾药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1 一、药品基本情况 药品名称：缩宫素注射液 药品名称：醋酸奥曲肽注射液 剂型：注射剂 注册证号：DRP-16801 二、药品相关的信息 缩宫素注射液主要用于引产、催产、以及产后、流产后因宫缩无力或缩复不 良而引起的子宫出血；了解胎盘储备功能（催产素激惹试验）。由 PAR STERILE PRODUCTS 研发，最早于 1980 年在美国上市。1994 年 10 月，上药第一生化的 缩宫素注射液在国内获批上市。截至本公告日，公司针对该药品在菲律宾的上市 未投入额外的研发费用，仅注册 ...

重要内容提示： 投资者可于 2025 年 08 月 22 日（星期五）至 08 月 28 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2025 年 8 月 28 日盘 后发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 08 月 29 日（星期五）15:0 0-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：601607 证券简称：上海医药 公告编号：临 2025-078 上海医药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、参加人员 本次投资者说明会以音频形式召开，公司将针对 2025 年半年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就 ...

Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates from the Philippines Food and Drug Administration for its Oxytocin Injection and Acetate Octreotide Injection, allowing these products to be marketed [2] Group 1 - Shanghai Pharmaceuticals announced the approval of its Oxytocin Injection and Acetate Octreotide Injection for sale in the Philippines [2] - The approval signifies a potential expansion of the company's market presence in Southeast Asia [2]

Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates from the Philippines Food and Drug Administration for its oxytocin injection and octreotide acetate injection, allowing for market entry in the Philippines [1] Group 1: Product Approval - The oxytocin injection is primarily used for induction and labor [1] - The octreotide acetate injection is mainly used for treating acromegaly [1] Group 2: Financial Implications - The company did not incur additional R&D expenses for the product registration, with only registration costs amounting to approximately RMB 50,000 [1] - The approval signifies the company's eligibility to sell these products in the Philippine market, which is expected to positively impact its overseas market expansion [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceutical First Biochemical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the oxytocin injection and octreotide acetate injection, allowing these drugs to be marketed [1] Group 1: Product Approvals - The oxytocin injection is primarily used for induction of labor, postpartum hemorrhage, and assessing placental reserve function [1] - The octreotide acetate injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the approval of Oxytocin Injection and Acetate Octreotide Injection for market launch [1] Group 1: Product Approvals - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is mainly used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical, has received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines, allowing them to enter the market without significant R&D costs [1] Group 1: Product Details - Oxytocin is used for induction of labor and was approved in China in 1994 [1] - Octreotide acetate is used for treating acromegaly and was approved in China in 2006, passing the consistency evaluation for generic drugs in 2022 [1] Group 2: Market Impact - The sales forecast for oxytocin in the Philippines is estimated at $970,000 in 2024 [1] - The approval of these drugs is expected to help expand the company's overseas market presence [1] Group 3: Financial Considerations - The registration costs for these drugs were approximately 50,000 yuan, with no additional R&D expenses incurred [1] - Sales may face uncertainties due to factors such as policy changes and exchange rate fluctuations [1]

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

Market Overview - The Shanghai Composite Index is at 3777.53 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 1,949.327 billion yuan [1] Stocks Breaking Annual Line - A total of 28 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Meihua Medical: 13.20% - Changhong Meiling: 3.88% - Kangle Weishi: 3.73% [1] Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Spring Airlines: 0.02% - Qingdao Port: 0.07% - Shanghai Pharmaceuticals: 0.08% [2] Performance of Selected Stocks - Meihua Medical shows a daily increase of 16.34% with a turnover rate of 29.76% [1] - Changhong Meiling has increased by 5.74% with a turnover rate of 6.32% [1] - Kangle Weishi has risen by 3.83% with a turnover rate of 3.18% [1] Additional Notable Stocks - Other stocks with notable performance include: - Mindray Medical: 4.41% increase, 1.15% turnover [1] - CNOOC Services: 2.70% increase, 0.67% turnover [1] - Qifeng New Materials: 4.08% increase, 4.75% turnover [1]

Market Overview - The Shanghai Composite Index is at 3781.13 points, above the annual line, with a change of 0.40% [1] - The total trading volume of A-shares is 1,193.158 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including Meihua Medical, *ST Aowei, and Pianzaihuang, showing divergence rates of 14.13%, 2.94%, and 2.77% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include China Wuyi, Huilun Crystal, and Zhuoshengwei [1] Top Stocks by Divergence Rate - Meihua Medical (301363) has a significant increase of 17.30% with a turnover rate of 23.04% and a divergence rate of 14.13% [1] - *ST Aowei (002231) increased by 3.12% with a turnover rate of 7.79% and a divergence rate of 2.94% [1] - Pianzaihuang (600436) rose by 3.70% with a turnover rate of 1.03% and a divergence rate of 2.77% [1] Additional Notable Stocks - Tongrentang (600085) increased by 1.93% with a divergence rate of 1.77% [1] - Maire Medical (300760) rose by 3.40% with a divergence rate of 1.53% [1] - Other stocks with minor divergence rates include Aima Technology (603529) and China Railway Construction (601186) with divergence rates of 1.06% and 0.96% respectively [1]